Epidemiological aspects of rheumatoid arthritis patients affected by oral bisphosphonate-related osteonecrosis of the jaws

Head & Face Medicine

Elcio Marcantonio Junior¹  Rosemary Adriana Chierici Marcantonio¹  Alliny Souza Bastos¹  Nicolau Conte-Neto¹ 

[1] UNESP- Univ. Estadual Paulista, School of Dentistry, Department of Diagnosis and Surgery, Division of Periodontology, Rua Humaitá, 1680, 14801-903 Araraquara, SP, Brazil

关键词: Osteonecrosis;    Jaws;    Bisphosphonate;    Rheumatoid arthritis;   

Others  :  819395
DOI  :  10.1186/1746-160X-8-5

 received in 2011-10-18, accepted in 2012-03-01,  发布年份 2012

【 摘 要 】

This literature review aims to evaluate the epidemiologic profile of patients with rheumatoid arthritis (RA) that developed a bisphosphonate-related osteonecrosis that affect the jaws (BRONJ), including demographic aspects, as well as clinical and therapeutic issues. A search of PUBMED/MEDLINE, Scopus, and Cochrane databases from January 2003 to September 2011 was conducted with the objective of identifying publications that contained case reports regarding oral BRONJ in RA patients. Patients with RA who develop oral BRONJ are usually women above 60 years taking steroids and long-term alendronate. Most of them have osteoporosis, and lesions, triggered by dental procedures, are usually detected at stage II in the mandible. Although there is no accepted treatment protocol, these patients seem to have better outcomes with conservative approaches that include antibiotic therapy, chlorhexidine, and drug discontinuation.

【 授权许可】

   
2012 Neto et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al.: Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88:2961-2974.
• [2]Breuil V, Euller-Ziegler L: Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 2006, 73:349-354.
• [3]Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62:527-534.
• [4]Marunick M, Miller R, Gordon S: Adverse oral sequelae to bisphosphonate administration. J Mich Dent Assoc 2005, 87:44-49.
• [5]Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B: American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. J Oral Maxillofac Surg 2009, 67:2-12.
• [6]Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S: Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007, 18:1363-1370.
• [7]Malden NJ, Pai AY: Oral bisphosphonate associated osteonecrosis of the jaws: three case reports. Br Dent J 2007, 203:93-97.
• [8]Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, et al.: Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2007, 92:1172-1175.
• [9]Marx RE, Cillo JE, Ulloa JJ: Oral bisphosphonates induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007, 65:2397-2410.
• [10]Hamada S: Osteonecrosis of jaw associated with oral application of bisphosphonates. J Oral Maxillofac Surg 2007, 65:43.
• [11]Barrow SY: Is your knowledge up-to-date? Int J Dent Hyg 2010, 8:319-323.
• [12]Junquera L, Gallego L, Cuesta P, Pelaz A, de Vicente JC: Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases. Am J Otolaryngol 2009, 30:390-395.
• [13]Mehanna P, Goddard R: Bisphosphonate associated osteonecrosis: an unusual case. Aust Dent J 2010, 55:311-313.
• [14]Favia G, Pilolli GP, Maiorano E: Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. J Rheumatol 2009, 36:2780-2787.
• [15]Kwon YD, Kim YR, Choi BJ, Lee DW, Kim DY: Oral bisphosphonate-related osteonecrosis of the jaws: favorable outcome after bisphosphonate holiday. Quintessence Int 2009, 40:277-278.
• [16]Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF: Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 2009, 140:61-66.
• [17]Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al.: Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010, 68:243-253.
• [18]Shin EY, Kwon YH, Herr Y, Shin SI, Chung JH: Implant failure associated with oral bisphosphonate-related osteonecrosis of the jaw. J Periodontal Implant Sci 2010, 40:90-95.
• [19]Park W, Kim NK, Kim MY, Rhee YM, Kim HJ: Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases. Osteoporos Int 2010, 21:527-533.
• [20]Manfredi M, Merigo E, Guidotti R, Meleti M, Vescovi P: Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int J Oral Maxillofac Surg 2011, 40:277-284.
• [21]Conte-Neto N, Bastos AS, Chierici-Marcantonio RA, Marcantonio E Jr: Oral bisphosphonate-related osteonecrosis of the jaws in rheumatoid arthritis patients: a critical discussion and two case reports. Head Face Med 2011, 27:1-7.
• [22]Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS: Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 2008, 121:475-483.e3.
• [23]Filleul O, Crompot E, Saussez S: Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010, 136:1117-1124.
• [24]Mavrokokki T, Cheng A, Stein B, Goss A: Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007, 65:415-423.
• [25]Felsenberg D, Hoffmeister B, Amling M, Mundlos S, Seibel MJ, Fratzl P: Kiefernekrosen nach hoch dosierter bisphosphonattherapie. Deutsches Arzteblatt 2006, 103:A3078-A3080.
• [26]Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al.: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the american society for bone and mineral research. J Bone Miner Res 2007, 22:1479-1491.
• [27]Sambrook P, Olver I, Goss A: Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician 2006, 35:801-803.
• [28]Yip RML: Bisphosphonates and osteonecrosis of the jaw. Hong Kong Bull Rheum Dis 2008, 8:19-25.
• [29]Joffe I, Epstein S: Osteoporosis associated with rheumatoid arthritis: pathogenesis and management. Semin Arthritis Rheum 1991, 20:256-272.
• [30]Baqain ZH, Sawair FA, Tamimi Z, Bsoul N, Al Edwan G, Almasad JK, et al.: Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospital. Ann R Coll Surg Engl 2010, 92:489-494.
• [31]Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al.: Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009, 27:5356-5362.
• [32]Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, et al.: Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 2006, 17:716-723.
• [33]Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al.: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005, 23:8580-8587.
• [34]Hoff AO, Toth BB, Altundag K, Guarneri V, Adamus A, Nooka AK, et al.: Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006, 24:8528.
• [35]Schiffrin EJ, Morley JE, Donnet-Hughes A, Guigoz Y: The inflammatory status of the elderly: the intestinal contribution. Mutat Res 2010, 690:50-56.
• [36]Johnson TE: Recent results: biomarkers of aging. Exp Gerontol 2010, 41:1243-1246.
• [37]Misawa Y, Kageyama T, Moriyama K, Kurihara S, Yagasaki H, Deguchi T, et al.: Effect of age on alveolar bone turnover adjacent to maxillary molar roots in male rats: a histomorphometric study. Arch Oral Biol 2007, 52:44-50.
• [38]Semba I, Funakoshi K, Kitano M: Histomorphometric analysis of age changes in the human inferior alveolar artery. Arch Oral Biol 2001, 46:13-21.
• [39]Kulikov VY, Fridman YM, Fomin AN: Role of oxidative stress in mechanisms of premature aging in shift labor workers. Alaska Med 2007, 49:81-84.
• [40]Maines E, Monti E, Doro F, Morandi G, Cavarzere P, Antoniazzi F: Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw. J Bone Miner Metab 2011, in press.
• [41]Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux FH, Rauch F: Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr 2008, 153:719-720.
• [42]Markenson JA: Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis. Semin Arthritis Rheum 1991, 21:4-12.
• [43]American Dental Association Council on Scientific Affairs: Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006, 137:1144-1150.
• [44]Barrett JH, Brennan P, Fiddler M, Silman A: Breast-feeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. Arthritis Rheum 2000, 43:1010-1015.
• [45]Tseng LN, Sheu WH, Ho ES, Lan HH, Hu CC, Kao CH: Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women. Metabolism 2006, 55:741-747.
• [46]Morioka M, Kamizono A, Takikawa H, Mori A, Ueno H, Kadowaki S, et al.: Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens. Bioorg Med Chem 2010, 18:1143-1148.
• [47]Marx RE, Sawatari Y, Fortin M, Broumand V: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005, 63:1567-1575.
• [48]Kos M, Luczak K: Bisphosphonates promote jaw osteonecrosis through facilitating bacterial colonization. Biosci Hypotheses 2009, 2:34-36.
• [49]Siris ES, Pasquale MK, Wang Y, Watts NB: Estimating bisphosphonate use and fracture reduction among U.S. women age 45 and older, 2001-2008. J Bone Miner Res 2011, 23:3-11.
• [50]Chapurlat RD, Delmas PD: Drug insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2006, 2:211-219.
• [51]Arce K, Assael LA, Weissman JL, Markiewicz MR: Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg 2009, 67:75-84.
• [52]Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al.: Bisphosphonate-related osteonecrosis of the jaw: position paper from the allied task force committee of Japanese society for bone and mineral research, Japan osteoporosis society, Japanese society of periodontology, Japanese society for oral and maxillofacial radiology, and Japanese society of oral and maxillofacial surgeons. J Bone Miner Metab 2010, 28:365-383.